VAH therapy before stem cell transplant for relapsed/refractory AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of drugs called VAH as a bridge to a stem cell transplant for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. It may help you if you have a specific genetic change (RUNX1::RUNX1T1) and are otherwise healthy enough for a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 14 and 70 years old.
- Your leukemia must have come back after treatment (relapsed) or not responded to standard therapy (refractory).
- You must have a specific genetic change called RUNX1::RUNX1T1 in your leukemia cells.
- You must be in good enough health to walk and take care of yourself (ECOG score 0-2).
- Your heart, liver, and kidneys must be working well enough (checked with blood tests and an echocardiogram).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving Venetoclax and Azacitidine (VA) after your first remission helps keep you in remission before a stem cell transplant. It's for people with intermediate-risk AML who are planning to have a donor transplant.
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
This trial tests a new combination of chemotherapy drugs before a stem cell transplant for people with acute myeloid leukemia (AML) in first remission who are not very fit or have other health problems. The goal is to make the transplant safer for these patients.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial tests a combination of two drugs (venetoclax and azacitidine) followed by a stem cell transplant from a donor for patients with a specific type of acute myeloid leukemia (AML) that has low bone marrow cell count or has developed from a prior blood disorder. The goal is to control the disease and give you a chance at a cure through transplantation.
This trial tests a new drug combination (VAC) for people with acute myeloid leukemia (AML) who did not improve after standard VA treatment. It is for those who cannot have strong chemotherapy due to age or health problems.
Hear when a new Relapse Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.